Contribution of avanidipine metabolites with slow binding kinetics to the vasodilating activity of avanidipine

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 355, Issue 1, 1996, Pages 119-125

  Miyoshi, Kazuhisa ^a   Miyake, Hidekazu ^a   Ichihara, Kenji ^b   Kamei, Hiroyuki ^b   Nagasaka, Mitsuaki ^b  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b Maruko Pharmaceutical Co Ltd   (Japan)

Author keywords

1,4 Dihydropyridines; Aranidipine; Binding study; Ca2+ channel antagonist; Metabolites; Slow kinetics

Indexed keywords

ARANIDIPINE; DRUG METABOLITE; NIFEDIPINE; 2 HYDROXYPROPYLMETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 (2 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLATE; 2-HYDROXYPROPYLMETHYL-1,4-DIHYDRO-2,6-DIMETHYL-4-(2-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE; CALCIUM; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; DIHYDROPYRIDINE DERIVATIVE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; DOG; DRUG RECEPTOR BINDING; FEMALE; FEMORAL ARTERY FLOW; GUINEA PIG; INTRAARTERIAL DRUG ADMINISTRATION; MALE; NONHUMAN; VASODILATATION; ANIMAL; BLOOD FLOW; DRUG EFFECT; KINETICS; METABOLISM;

ANIMALS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CALCIUM CHANNELS, L-TYPE; DIHYDROPYRIDINES; DOGS; FEMALE; GUINEA PIGS; KINETICS; MALE; NIFEDIPINE; REGIONAL BLOOD FLOW; VASODILATOR AGENTS;

EID: 0030614736     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00004909     Document Type: Article

References (24)

1. Boyd RA, Giacomini JC, Wong FM, Nelson WL, Giacomini KM (1987) Comparison of binding affinities and negative inotropic potencies of the 1,4-dihydropyridine calcium channel blockers in rabbit myocardium. J Pharmacol Exp Ther 243:118-125
2. 3H]-nitrendipine binding sites. Br J Pharmacol 82:309-320
3. 3H]-PN-200-110 binding to cell membranes and intact strips of portal vein smooth muscle: characterization and modulation by membrane potential and divalent cations. Br J Pharmacol 97:256-262
4. Dunn OJ (1961) Multiple comparisons among means. J Am Statist Assoc 56:52-64
5. Fleckenstein A (1977) Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol 17:149-166
6. Glossmann H, Ferry DR (1986) Assay for calcium channels. Methods Enzymol 109:513-551
7. Godfraind T, Miller R, Wibo M (1986) Calcium antagonism and calcium entry blockade. Pharmacol Rev 38:321-416
8. 3H]nifedipine binding sites in rabbit myocardium. Eur J Pharmacol 85:305-315
9. 2+ entry blocker, on α-adrenoceptor-mediated pressor responses in pithed rats. Eur J Pharmacol 238:283-289
10. Kanda A, Haruno A, Miyake H, Nagasaka M (1992) Antihypertensive effects of MPC-1304, a novel calcium antagonist, in experimental hypertensive rats and dogs. J Cardiovasc Pharmacol 20:723-730
11. 45Ca in rabbit aortic smooth muscle by norepinephrine and potassium after exposure to lanthanum and low temperature. J Pharmacol Exp Ther 211:86-92
12. Karasawa A, Kubo K (1988) Calcium antagonistic effects and the in vitro duration of actions of KW-3049, a new 1,4-dihydropyridine derivative, in isolated canine coronary arteries. Jpn J Pharmacol 47:35-44
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
14. 3H]nitrendipine binding in smooth and cardiac muscle. J Pharmacol Exp Ther 230:607-613
15. Mason RP, Campbell SF, Wang S-D, Herbette LG (1989) Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes. Mol Pharmacol 36:634-640
16. Miyoshi K, Kanda A, Miyake H, Ichihara K, Kamei H, Nagasaka M (1993) MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating action. Eur J Pharmacol 238:139-148
17. Nayler WG, Gu XH (1991) The unique binding properties of amlodipine: a long-acting calcium antagonist. J Hum Hypertens 5 [Suppl. 1]:55-59
18. Ohno S, Komatsu O, Mizukoshi K, Ichihara K, Nakamura Y, Morishima T, Sumita K (1986) Synthesis of asymmetric 4-aryl-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylates with vasodilating and antihypertensive activities. Chem Pharm Bull 34:1589-1606
19. Okabe K, Terada K, Kitamura K, Kuriyama H (1987) Selective and long-lasting inhibitory actions of the dihydropyridine derivative, CV-4093, on calcium currents in smooth muscle cells of the rabbit pulmonary artery. J Pharmacol Exp Ther 243:703-710
20. Okumura K, Ichihara K, Nagasaka M, Oda N, Tajima K (1993) Calcium entry blocking activities of MPC-1304 and of its enantiomers and metabolites. Eur J Pharmacol 235:69-74
21. Salomone S, Godfraind T (1993) Radioligand and functional estimates of the interaction of the 1,4-dihydropyridines, isradipine and lacidipine, with calcium channels in smooth muscle. Br J Pharmacol 109:100-106
22. Sarmiento JG, Janis RA, Katz AM, Triggle DJ (1984) Comparison of high affinity binding of calcium channel blocking drugs to vascular smooth muscle and cardiac sarcolemmal membranes. Biochem Pharmacol 33:3119-3123
23. Umeno Y, Matsushima E, Maniwa M, Marunaka T (1988) Gas chromatographic-negative-ion chemical ionization mass spectrometric determination of a new dihydropyridine calcium antagonist (MPC-1304) and its metabolites in human plasma and urine. J Chromatogr 434:123-133
24. Weiland GA, Molinoff PB (1981) Quantitative analysis of drug-receptor interactions: I. Determination of kinetic and equilibrium properties. Life Sci 29:313-330